Real Time PCR Based Detection of Hepatitis C Virus Major Genotypes in Chronic HCV Patients in Khyber Pakhtunkhwa

Nourin Mahmood 1, Sajid Ali 1, *, Jehanzeb Afridi 2, Bashir Ahmad 3, Ijaz Ali 4 and Fazal Jalil 1

1 Department of Biotechnology, Abdul Wali Khan University Mardan, Mardan, Pakistan
2 Peshawar Medical College, Peshawar, Pakistan
3 Centre of Biotechnology and Microbiology, University of Peshawar, Peshawar, Pakistan
4 COMSATS University Islamabad, Islamabad, Pakistan

* Corresponding author: Department of Biotechnology, Abdul Wali Khan university Mardan, Mardan, Pakistan. Email: sajid@awkum.edu.pk

Received 2018 June 17; Revised 2018 September 22; Accepted 2018 October 18.

Abstract

Background: Hepatitis C virus (HCV) has been classified into seven major and more than 100 quasi species. To treat hepatitis C patients, it is important to determine the type of HCV as it has been linked with treatment duration and outcome.

Objectives: The objective of the study was to find out HCV major genotypes using Taqman Probe based real time PCR assay and to compare prevalence of these with previous HCV genotype distribution using other methods in Khyber Pakhtunkhwa.

Methods: In this study, 100 actively infected patients were selected, referred by different physicians, and genotyping was done using Sacace real time PCR based assay.

Results: Among 100 patients, the most abundant major genotype was HCV 3, followed by genotype 1 and the untypable while genotype 2 was scarcely found.

Conclusions: The existing methodology confirmed the prevalence of major genotype 3, similar to that of previous methodologies and studies, however, with a slight shift of genotype 2 distribution.

Keywords: Hepatitis C Virus, Real Time Polymerase Chain Reaction, TaqMan, Interferon

1. Background

Hepatitis C virus (HCV) is a globally prevalent pathogen and the top trigger of death and morbidity (1). Hepatitis C virus prevalence in the last 15 decades have been shown to raise to 2.8%, estimated to be equal to > 185 millions of infection worldwide (2). Chronic HCV infection may possibly progress to severe liver disease, which includes cirrhosis and at some point, into hepatocellular carcinoma (3). Annually 3% - 4% of population is infected and thousands of deaths occur worldwide due to hepatitis C. Among infected individuals, 85% of sufferers advance into chronic stage and then to cirrhosis, 1% - 4% of the patients lead to hepatocellular carcinoma (HCC) (4).

On the basis of phylogenetic and sequence evaluation, HCV has been classified into one to seven key genotypes (5). These strains differ from one another at 30% - 35% nucleotide sites. These genotypes have been further classified into 67 confirmed and 20 provisional subtypes and these are distinct at < 15% of the nucleotide sites (6). Geographical distribution of HCV genotypes is extremely complex, it has been known that genotypes known as epidemic genotypes, 1, 2, and 3 have worldwide distribution and account for a massive proportion of HCV infection in well developed countries (7-9). Other genotypes called as endemics are comparatively rare and are present in quite restricted regions. Endemic strains from genotype 1 and 2 are present in West Africa, 3 in South Asia, 4 in Central Africa and Middle East, 5 in Southern Africa, and 6 in South East Asia (10). Genotype 7 has been isolated in Canada from Central African immigrants (11).

Distinct techniques have been utilized to figure out genotypes, amongst the most frequently employed are, direct sequencing of a distinct polymerase chain response (PCR)-amplified portion of the viral genome obtained from a patient sample, followed by phylogenetic examination restriction fragment length polymorphism (RFLP) (5, 12). PCR amplification, with variety-distinct primers, has been used to figure out HCV genotype, however, sensitivity and specificity parameters of this approach demand even more evaluation (4, 12, 13). DNA hybridization technologies, including LiPA, are commercially offered to figure out HCV genotypes (13). Lastly, kinetic PCR with fluorescence reso-
nance vitality transfer (FRET) probes or intercalating dyes has been utilized to detect genotype HCV in a single tube reaction utilizing dissociation curve analysis (14, 15).

Everywhere in the world treatment strategies are based on HCV genotypes, therefore, prior to therapy, it’s essential to determine particular genotype for the sake of deciding type and duration of antiviral therapy either direct-acting antiviral agents (DAA) or indirect acting antiviral agents (AA). In Pakistan, HCV prevalence is increasing day by day and it is almost in the range of 3% - 5% (16), depending on the regions within Pakistan. Here most of the people determine HCV genotype using Ohno et al. (17), HCV genotyping method. However, discrepancy exists in genotyping. As some time different laboratories issue different genotypes or sub types of the same sample. This might be due to the in-house methods that have been developed. Secondly, treatment response has been linked with major HCV genotypes.

### 2. Objectives

In order to minimize these discrepancies, we employed real time PCR based genotyping method, based on principle of Florence hybridization (TaqMan Probe assay).

### 3. Methods

#### 3.1. Ethics Statement

This study was approved by the Ethical Committee of Department of Biotechnology of Abdul Wali Khan University Mardan and Mercy Teaching Hospital, Peshawar, Khyber Pakhtunkhwa, reference number Awkum-125.

#### 3.2. Patients’ Selection and Blood Collection

This study included 100 patients. Patients were selected who were referred by physicians, either with relapse history or naïve patients. From each patient, 5 mL of blood was taken with informed consent. Blood was centrifuged at 8000 rpm for 5 minutes and serum was stored at -4°C until further use.

#### 3.3. RNA Extraction

RNA extraction was done as previously performed (16). Briefly, the following procedure, according to manufacturer’s instructions (Macherey-Nagel GmbH, Germany), was followed. A total of 200 µl lysis solutions was taken in an eppendorp tube, added 200 µl serum sample, mixed it with the help of shaking, added 280 µl ethanol into the mixture, and transferred all of the above mixture into the receiver tube having spin column. After centrifugation, the receiver tube was discarded and transferred the spin column to another receiver tube, washed twice with the washing solution of the spin column, and finally 60 µl of elution buffer was added into the spin column and after slight centrifugation, HCV RNA was obtained.

#### 3.4. Genotype Determination

To find out the genotype in each of the subject sample, Sacace real time PCR based genotyping kit (Sacace, Italy) was used. For each of the subjects, genotyping was done according to manufacturer’s instruction. Simply, master mix was prepared as shown in Table 1. All the above ingredients were mixed and added to specialized PCR tube, 15 µl master mix along with 10 µl extracted RNA (total volume of the mix was equal to 25 µl). Similarly,10 µl controls, HCV genotype 1, 2, and 3 and dH20 was added to the tubes labeled as positive and negative control, respectively, and centrifuged slightly; all PCR tubes were placed in the PCR machine, Smart Cycler (Cepheid, USA). Set thermal protocols (Table 2) designated the sites and started the run. After two hours, the results and analysis were given and their interpretation is given in Table 3. The above procedure was adopted for all of the 100 samples. Positive and negative controls were added for validation of the results.

#### 4. Results and Discussion

All sera samples were processed for genotyping using commercial Sacace real time PCR kit. The primer and probe was designed using 5 UTR region of HCV genome. The probe was tagged with FAM, CY3, and CY5. Interpretation of results is given in Table 3. While the percent prevalence is out of 100 subject population, the major genotype found was 3 (83%), followed by genotype 1 (8%) and untypable (7%) while the least genotype was 2 (2%) (Figure 1). While no amplification was found in negative control.

Chronic viral hepatitis and its associated complications with progressive liver disease are severe health problem worldwide. In Pakistan, its prevalence varies in different geographical regions and may range from 2% - 7% (18).
This study was conducted to figure out the percent prevalence of major HCV types using the Real-Time-based typing system (Sacace, Italy) for the first time in the Khyber Pakhtunkhwa province of Pakistan. The results indicated that major HCV genotype was type 3 (83%), followed by type 1 (8%) while a number of cases were untypeable as well (Figure 1). Previous studies in Pakistan, and even in Khyber Pakhtunkhwa, have already reported higher prevalence of the genotype 3a (16), which seem in line with our study. However, prevalence of genotype 1 is comparatively higher than the previous studies. This higher percentage indicates a new shift in HCV epidemiology, although the presence of genotype 1a and 1b has been reported by other studies conducted in Pakistan (16). A more recent study conducted in the Khyber Pakhtunkhwa province has also reported a shift the distribution of HCV types with higher percentage of HCV 1b or its mixed infections (21).

Presence of the ‘untypeable’ genotypes (Figure 1) has also been shown by other studies (16) however, its share in our study (7%) is higher than the previous reports. This might be due to low viral titer in the blood of the patients and absence of viral RNA in the serum samples or limitations of the present assay used, as this assay could detect only major genotypes 1 - 3. Prevalence of genotype 2 (Figure 1) has also been shown in studies (22), however, the percentage of existence of this particular genotype shown in this study is lower than previous studies (1, 16, 23).

4.1. Conclusions

Although a significant prevalence of major genotype 3 was found in the studied population, the overall pattern of HCV major types distribution indicates a shift in their distribution in contrast to majority of the studies conducted earlier.
Acknowledgments
Authors are thankful to the Real Time PCR Laboratory for providing practice space and health professionals for referring HCV patients.

Footnotes

Authors’ Contribution: Nourin Mahmood performed the experimental work, Sajid Ali and Bashir Ahmad designed the research work, Jehanzeb Afridi provided samples, Sajid Ali and Nourin Mahmood prepared manuscript, and Fazal Jalil and Ijaz Ali reviewed the work.

Financial Disclosure: None declared.

Funding/Support: None declared.

References

1. Attaullah S, Khan S, Ali I. Hepatitis C virus genotypes in Pakistan: A systematic review. Virol J. 2011;8:433. doi: 10.1186/1743-422X-8-433. [PubMed: 21902822]. [PubMed Central: PMC378528].
2. Safi SZ, Badshah Y, Waheed Y, Fatima K, Tahir S, Shinwari A, et al. Distribution of hepatitis C virus genotypes, hepatic steatosis and their correlation with clinical and virological factors in Pakistan. Asian Biomed. 2010;4(2):253-62. doi: 10.2478/abm-2010-0032.
3. Ali A, Ahmed H, Idrees M. Molecular epidemiology of hepatitis C virus genotypes in Khyber Pakhtoonkhaw of Pakistan. Virol J. 2010;7:203. doi: 10.1186/1743-422X-7-203. [PubMed: 20796270]. [PubMed Central: PMC2936312].
4. Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis. 2008;8:369. doi: 10.1186/1471-2334-8-369. [PubMed: 18498666]. [PubMed Central: PMC2409346].
5. Umar M, Bushra HT, Ahmad M, Data A, Ahmad M, Khurram M, et al. Hepatitis C in Pakistan: A review of available data. Hepat Mon. 2010;10(3):205-14. [PubMed: 22308461]. [PubMed Central: PMC2690083].
6. Sultan MT, Rahman MM, Begum S. Epidemiology of hepatitis C virus (HCV) infection. J Bangladesh Coll Phys Surg. 2010;27(3):460-5. doi: 10.3329/bcp.v27i3.4294.
7. Butt S, Idrees M, Akbar H, ur Rehman I, Awan Z, Afzal S, et al. The changing epidemiology pattern and frequency distribution of hepatitis C virus in Pakistan. Infect Genet Evol. 2009;10(5):595-600. doi: 10.1016/j.megev.2010.04.012. [PubMed: 20438863].
8. Pybus OG, Markov PW, Vu A, Tatem AJ. Investigating the endemic transmission of the hepatitis C virus. Int J Parasitol. 2007;37(9-10):439-49. doi: 10.1016/j.ijpara.2007.04.009. [PubMed: 17521655].
9. Khan A, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, et al. Epidemiologic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol. 2009;81(7):1189-97. doi: 10.1002/jmv.21466. [PubMed: 19475617].
10. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. doi: 10.1002/hep.27259. [PubMed: 25069559]. [PubMed Central: PMC4309318].
11. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. Hepatol. 2014;61(3 Suppl):S5-57. doi: 10.1002/hep.24077. [PubMed: 25086286].
12. Yao E, Tavis JF. Virome-C. Study Group. A general method for nested RT-PCR amplification and sequencing the complete HCV genotype open reading frame. Virol J. 2005;2:88. doi: 10.1186/1743-422X-2-88. [PubMed: 16321149]. [PubMed Central: PMC325262].
13. Yang R, Cong X, Du S, Fei R, Rao H, Wei L. Performance comparison of the versant HCV genotype 2.0 assay (LiPA) and the Abbott retime HCV genotype II assay for detecting hepatitis C virus genotype 6. J Clin Microbiol. 2014;52(10):3885-92. doi: 10.1128/JCM.00882-14. [PubMed: 25000877]. [PubMed Central: PMC4187793].
14. Bhattacharya D, Ansari IH, Mehle A, Striker R. Fluorescence resonance energy transfer-based intracellular assay for the conformity of hepatitis C virus drug target NS5A. J Virol. 2012;86(11):5827-86. doi: 10.1128/JVI.00645-12. [PubMed: 22623794]. [PubMed Central: PMC3421644].
15. Corby J, Biener G, Raicu V, Frick D. FRET studies examining the interaction of hepatitis C NS3 helicase and human DDX/H box helicases. FASEB J. 2016;30(1_supplement):600.23.
16. Ali S, Ali I, Azam S, Ahmad B. Frequency distribution of HCV genotypes among chronic hepatitis C patients of Khyber Pakhtunkhwa. Virol J. 2011;8:393. doi: 10.1186/1743-422X-8-393. [PubMed: 21525506]. [PubMed Central: PMC3103302].
17. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35(1):201-7. doi: 10.1128/JCM.35.1.201-207.1997. [PubMed: 8968908]. [PubMed Central: PMC229519].
18. Umer M, Iqbal M. Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data. World J Gastroenterol. 2016;22(4):684-700. doi: 10.3748/wjg.v22.i4.684. [PubMed: 26891953]. [PubMed Central: PMC4729999].
19. Rasheed A, Ullah S, Naeem S, Zubair M, Ahmad W, Hussain Z. Occurrence of HCV genotypes in different age groups of patients from Lahore, Pakistan. Adv Life Sci. 2014;2(2):39-95.
20. Bosan A, Qureshi H, Bile KM, Ahmad I, Hafiz R. A review of hepatitis viral infections in Pakistan. Pak J Med Assoc. 2010;60(2):340-5. doi: 10.1186/1743-422X-8-327. [PubMed: 21385621].
21. Gul A, Zahid N, Ahmed J, Zahir F, Khan IA, Ali I. Molecular characterization of hepatitis C virus 3a in Peshawar. BMC Infect Dis. 2016;16:163. doi: 10.1186/s12879-016-1488-0. [PubMed: 27095071]. [PubMed Central: PMC4836082].
22. ur Rehman I, Ullah I, Ali I, Khan IA, Iqbal A, Khan S, et al. Active hepatitis C infection and HCV genotypes prevalent among the IDUs of Khyber Pakhtunkhwa. Virol J. 2011;8:327. doi: 10.1186/1743-422X-8-327. [PubMed: 2176541]. [PubMed Central: PMC483596].
23. Rehman IU, Idrees M, Ali M, Ali I, Butt S, Hussain A, et al. Hepatitis C virus genotype 3a with phylogenetically distinct origin is circulating in Pakistan. Genet Vaccines Ther. 2018;7:12. doi: 10.1186/s12987-015-0056-9-2. [PubMed: 28110224]. [PubMed Central: PMC5023652].